OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
FNTU.CD56

Fluent Corp

Healthcare Facilities & ServicesVerified

Fluent Corp's capital structure is characterized by a negative equity position of $80.96 million and a debt-to-equity ratio of -1.73, indicating a leveraged position with liabilities exceeding equity. The company holds $8.91 million in cash and equivalents, which is insufficient to cover its $139.86 million in long-term debt, resulting in a net cash position that is negative after subtracting total debt. Operating cash flow is negative at $588,000, and capital expenditures amounted to $14.40 million in the latest period. Profitability metrics are not available in the valuation snapshot, but the negative equity and high leverage suggest financial stress. The company's operating cash flow is negative, and capital expenditures are significant relative to its cash reserves, indicating a capital-intensive business model with limited cash generation. These factors suggest that Fluent Corp is underperforming relative to typical industry metrics, which emphasize sustainable cash flow and manageable debt levels. Geographic and segment exposure data are not provided in the input, but the company's revenue concentration is implied to be within the pharmaceuticals segment, as per its classification. Without disclosed geographic breakdowns, it is unclear whether the company is exposed to regional market risks or has diversified revenue streams. The company's growth trajectory is uncertain, as the latest actual revenue of $97.29 million is lower than the reported revenue of $86.69 million, suggesting a potential decline in performance. The absence of forward-looking guidance and the negative operating cash flow raise concerns about the company's ability to sustain or grow revenue in the near term. Risk factors include medium liquidity risk due to insufficient cash reserves to cover long-term debt and a negative equity position. The dilution risk is assessed as low, but the company's negative equity and high leverage could lead to further dilution if additional financing is required. The risk assessment highlights the need for close monitoring of the company's liquidity position and capital structure. Recent events include the latest financial reporting, which shows a decline in revenue and negative operating cash flow. No recent filings or transcripts are provided in the input, so the company's strategic direction and operational performance remain opaque.

30-day price · FNTU.CD(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyFluent Corp
TickerFNTU.CD
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Fluent Corp operates in the healthcare facilities and services industry, focusing on pharmaceuticals.

Classification. Fluent Corp is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Fluent Corp's capital structure is characterized by a negative equity position of $80.96 million and a debt-to-equity ratio of -1.73, indicating a leveraged position with liabilities exceeding equity. The company holds $8.91 million in cash and equivalents, which is insufficient to cover its $139.86 million in long-term debt, resulting in a net cash position that is negative after subtracting total debt. Operating cash flow is negative at $588,000, and capital expenditures amounted to $14.40 million in the latest period. Profitability metrics are not available in the valuation snapshot, but the negative equity and high leverage suggest financial stress. The company's operating cash flow is negative, and capital expenditures are significant relative to its cash reserves, indicating a capital-intensive business model with limited cash generation. These factors suggest that Fluent Corp is underperforming relative to typical industry metrics, which emphasize sustainable cash flow and manageable debt levels. Geographic and segment exposure data are not provided in the input, but the company's revenue concentration is implied to be within the pharmaceuticals segment, as per its classification. Without disclosed geographic breakdowns, it is unclear whether the company is exposed to regional market risks or has diversified revenue streams. The company's growth trajectory is uncertain, as the latest actual revenue of $97.29 million is lower than the reported revenue of $86.69 million, suggesting a potential decline in performance. The absence of forward-looking guidance and the negative operating cash flow raise concerns about the company's ability to sustain or grow revenue in the near term. Risk factors include medium liquidity risk due to insufficient cash reserves to cover long-term debt and a negative equity position. The dilution risk is assessed as low, but the company's negative equity and high leverage could lead to further dilution if additional financing is required. The risk assessment highlights the need for close monitoring of the company's liquidity position and capital structure. Recent events include the latest financial reporting, which shows a decline in revenue and negative operating cash flow. No recent filings or transcripts are provided in the input, so the company's strategic direction and operational performance remain opaque.
Key takeaways
  • Fluent Corp has a negative equity position and a debt-to-equity ratio of -1.73, indicating a highly leveraged capital structure.
  • The company's operating cash flow is negative, and capital expenditures are significant relative to its cash reserves.
  • Revenue concentration is implied to be within the pharmaceuticals segment, with no geographic diversification data available.
  • The latest actual revenue is lower than the reported revenue, suggesting a potential decline in performance.
  • The company faces medium liquidity risk and a negative equity position, which could lead to further dilution if additional financing is required.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$86.7M
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow-$588.0k
CapEx-$14.4M
Free cash flow
Total assets
Total liabilities$229.5M
Total equity-$81.0M
Cash & equivalents$8.9M
Long-term debt$139.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash-$131.0M
Current ratio
Debt/Equity-1.7
ROA
ROE
Cash conversion
CapEx/Revenue-16.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricFNTU.CDActivity
Op margin18.2% medp25 18.2% · p75 24.6%
Net margin14.7% medp25 11.7% · p75 28.1%
Gross margin19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-16.6%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity-173.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Observations
IR observations
Last actual revenue97,290,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:44 UTC#6ad19153
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:46 UTCJob: 6ac12958